Arene oxide metabolites of phenytoin may be involved in the pathogenesis of drug-induced hepatotoxicity. We examined individual susceptibility to toxicity from such metabolites by exposing human lymphocytes to metabolites generated by a murine hepatic microsomal system. Cells from 17 controls showed no toxicity at concentrations of phenytoin from 31 to 125 microM. Cells from three patients with phenytoin hepatotoxicity manifested dose-dependent toxicity from the metabolites. Phenytoin alone was not toxic to cells. The patients' dose-response curves resembled the response of control cells in which epoxide hydrolase (a detoxification enzyme for arene oxides) was inhibited. Detoxification of non-arene oxide metabolites (e.g., of acetaminophen) was normal in patients' cells. Cells from parents of two patients had intermediate responses. Cells from a sibling of one patient showed no toxicity; a sibling of another patient had a response similar to that of the patient. A heritable defect in response to arene oxides thus may predispose some patients to phenytoin hepatotoxicity.
This article has been cited by other articles:
Lu, W., Uetrecht, J. P.
(2008). Peroxidase-Mediated Bioactivation of Hydroxylated Metabolites of Carbamazepine and Phenytoin. Drug Metab. Dispos.
36: 1624-1636
[Abstract][Full Text]
Lin, D., Tucker, M J., Rieder, M. J
(2006). Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection. The Annals of Pharmacotherapy
40: 1594-1601
[Abstract][Full Text]
Svensson, C. K., Cowen, E. W., Gaspari, A. A.
(2001). Cutaneous Drug Reactions. Pharmacol. Rev.
53: 357-379
[Abstract][Full Text]
Pirmohamed, M., Lin, K., Chadwick, D., Park, B. K.
(2001). TNF{{alpha}} promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology
56: 890-896
[Abstract][Full Text]
Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., Gillam, E. M. J.
(2000). Phenytoin Metabolism by Human Cytochrome P450: Involvement of P450 3A and 2C Forms in Secondary Metabolism and Drug-Protein Adduct Formation. Drug Metab. Dispos.
28: 945-950
[Abstract][Full Text]
Reilly, T. P., MacArthur, R. D., Farrough, M. J., Crane, L. R., Woster, P. M., Svensson, C. K.
(1999). Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?. J. Pharmacol. Exp. Ther.
291: 1356-1364
[Abstract][Full Text]
Vittorio, C. C., Muglia, J. J.
(1995). Anticonvulsant Hypersensitivity Syndrome. Arch Intern Med
155: 2285-2290
[Abstract]
Wolkenstein, P., Charue, D., Laurent, P., Revuz, J., Roujeau, J.-C., Bagot, M.
(1995). Metabolic Predisposition to Cutaneous Adverse Drug Reactions: Role in Toxic Epidermal Necrolysis Caused by Sulfonamides and Anticonvulsants. Arch Dermatol
131: 544-551
[Abstract]
Roujeau, J. C., Stern, R. S.
(1994). Severe Adverse Cutaneous Reactions to Drugs. NEJM
331: 1272-1285
[Full Text]
Lisker-Melman, M., Hoofnagle, J. H.
(1989). Phenytoin Hepatotoxicity Masked by Corticosteroids. Arch Intern Med
149: 1196-1197
[Abstract]
Powers, N. G., Carson, S. H.
(1987). Idiosyncratic Reactions to Phenytoin. CLIN PEDIATR
26: 120-124
[Abstract]
SHEAR, N. H., SPIELBERG, S. P., GRANT, D. M., TANG, B. K., KALOW, W.
(1986). Differences in Metabolism of Sulfonamides Predisposing to Idiosyncratic Toxicity. ANN INTERN MED
105: 179-184
[Abstract]
Taylor, J. W., Stein, M. N., Murphy, M. J., Mitros, F. A.
(1984). Cholestatic Liver Dysfunction After Long-term Phenytoin Therapy. Arch Neurol
41: 500-501
[Abstract]
Previous
